Background
Genentech owned U.S. Patent No. 4,601,980 covering recombinant DNA methods for producing human growth hormone (hGH) — a critical therapeutic protein used to treat growth hormone deficiency in children and adults. Genentech had been a pioneer in recombinant hGH production, developing methods using genetically engineered bacteria to express the hGH protein. One characteristic of the bacterial expression system was that the process predominantly produced met-hGH — a form of hGH containing an extra methionine amino acid at the amino terminus — rather than the mature 191-amino acid hGH found naturally in the human body.
Bio-Technology General (BTG) and its Israeli affiliate developed their own recombinant hGH production method. Genentech sued BTG for infringement of the ‘980 patent. BTG defended by challenging the patent’s validity, arguing that the patent lacked enablement under 35 U.S.C. § 112 because the disclosed method predominantly produced met-hGH rather than mature hGH, and that this distinction made the patent’s disclosure insufficient to enable production of genuine human growth hormone. The district court had sided with BTG’s enablement challenge after trial. Genentech appealed.
The Court’s Holding
The Federal Circuit reversed in an opinion by Judge Newman, reinstating the jury’s verdict that the patent was valid and adequately enabled. The court found that the district court had misapplied the enablement standard and improperly second-guessed the jury’s factual findings.
The enablement requirement under § 112 requires that the specification teach a person of ordinary skill in the art how to make and use the claimed invention without undue experimentation. Critically, enablement is assessed based on what the patent claims — not against some external performance standard or a different product than the one claimed. The ‘980 patent’s claims covered a recombinant method for producing hGH. The fact that the process produced predominantly met-hGH did not defeat enablement, because (1) the claims encompassed the production of met-hGH as well as mature hGH, and (2) the specification and prior art knowledge together taught skilled practitioners how to practice the claimed method.
The court also emphasized the appropriate deference owed to jury verdicts on enabling disclosure questions. Enablement involves both legal and factual components. When a jury resolves the underlying factual questions — such as the level of ordinary skill in the art, the scope of the disclosure, and what a skilled practitioner would understand from it — those factual findings should be upheld if supported by substantial evidence. BTG’s own submissions to the FDA had shown that the hGH produced by Genentech’s method contained measurable amounts of mature hGH, which was consistent with Genentech’s enablement position.
Key Takeaways
- Enablement is assessed against the scope of the patent claims, not against an idealized product or process not mentioned in the claims — a patent claiming a production method is enabled if the specification teaches how to perform that method, even if the method produces a product that differs from the naturally occurring counterpart.
- When a claimed process produces a mixture of products (such as met-hGH and mature hGH), the patent is enabled if the claimed method is adequately disclosed — the ratio of products is a characteristic of the method, not an additional unstated limitation.
- Jury verdicts on enablement are entitled to substantial evidence review — when the jury resolves contested factual questions about the state of the art and the adequacy of disclosure, courts should defer to those findings absent clear error.
- A patent challenger’s own commercial and regulatory submissions (such as FDA applications) may be used as evidence against the challenger’s invalidity arguments — statements made to the FDA about the characteristics of a product made by the patented process can undermine an enablement challenge.
- In biotechnology patent cases, the distinction between a naturally occurring molecule and a recombinantly produced version (such as mature hGH versus met-hGH) is relevant to claim construction — if the claims encompass the produced form, enablement analysis focuses on whether the specification teaches production of that form.
Why It Matters
Bio-Technology General v. Genentech is an important early case on the enablement standard in the context of recombinant biotechnology patents. The case arose during the formative period of the biotechnology industry, when patents on recombinant protein production methods were among the most commercially valuable intellectual property in pharmaceutical development. The question of what constitutes “human growth hormone” — and whether a recombinantly produced form with a slight structural difference from the natural molecule is the same or different for patent purposes — is exactly the kind of issue that defines the scope of biotechnology patents.
The case also provides a useful reminder that enablement challengers cannot set up a moving target by defining the claimed invention as something that the patent never promised to produce. If the claims cover a method of producing a protein by recombinant means, and the specification teaches that method, the patent is enabled — even if the resulting protein differs in some respects from the naturally occurring molecule. For practitioners in pharmaceutical and biotechnology sectors, the case reinforces the importance of drafting claims and specifications that accurately describe the actual product produced by the claimed method, avoiding unintended gaps between the claimed invention and what the disclosed process actually makes.